Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel

The use of nitazoxanide has previously yielded successful results in vitro against the coronavirus. aim present study was to examine efficacy at an early stage among healthcare workers exhibiting symptoms COVID‑19. This a prospective carried out in 2020. Healthcare personnel who presented with COVID‑19 symptoms, different 3 hospitals were invited take Paramix (nitazoxanide), 500 mg orally, every 6 h for 2 days and then twice day 4 days. To compare hospitalization percentage, group respiratory viral infection without criteria also followed‑up. Over period months, 150 (111 women 39 men) (mean age, 36±10.6 years; range, 18‑68 years). Only one female medical doctor, nurse male from auxiliary services had be hospitalized death registered It thus concluded that previous coronavirus may prove useful SARS‑CoV‑2 as intervention avoid complications, decreasing expected number hospitalizations infected workers.